Last reviewed · How we verify
Erlotinib PO and Vidaza IV — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Erlotinib PO and Vidaza IV (Erlotinib PO and Vidaza IV) — New Mexico Cancer Research Alliance.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Erlotinib PO and Vidaza IV TARGET | Erlotinib PO and Vidaza IV | New Mexico Cancer Research Alliance | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Erlotinib PO and Vidaza IV CI watch — RSS
- Erlotinib PO and Vidaza IV CI watch — Atom
- Erlotinib PO and Vidaza IV CI watch — JSON
- Erlotinib PO and Vidaza IV alone — RSS
Cite this brief
Drug Landscape (2026). Erlotinib PO and Vidaza IV — Competitive Intelligence Brief. https://druglandscape.com/ci/erlotinib-po-and-vidaza-iv. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab